Pete Hendrickson

Radiation oncologist @DukeRadOnc| DUX factors, embryonic genome activation, and cancer

[David Kirsch, MD, PhD @DKirschMDPhD]

Just in time for #CTOS2024: Thrilled to share SU2C-SARC032 (NCT03092323), a randomized trial of pembrolizumab in Stage 3 extremity soft tissue sarcoma, now published @TheLancet!
https://t.co/P9lAyTX9NF
1/13
@SARCtrials
@SU2C
@ctosociety
@RadMedPM
@pmcancercentre
@UHN
@UofTDRO

[Stand Up To Cancer @SU2C]

Your donation dollars in action! 🙌A #StandUpToCancer-funded #research team unveiled an exciting #clinicaltrial breakthrough that reduces risk of #cancer relapse by 43% – for 2 of the most common types of soft tissue #sarcoma in adults, 2 years after treatment. Learn more: https://t.co/Z6cplKo9ML.

[Pete Hendrickson @pghendrickson]

Huge thanks to @ConquerCancerFd and @quadwfoundation for giving me this opportunity and for funding sarcoma research. Elated to join the growing network of QuadW researchers both near and far.

[Conquer Cancer, the ASCO Foundation @ConquerCancerFd]

Congratulations to this year's class of Conquer Cancer Grant and Award recipients! We can't wait to celebrate with you at #ASCO24! Full list of recipients: https://t.co/mCaRLSVLik

[Edward Grow, PhD @ControllingLMNT]

Excited to share our work on chromatin landscape remodeling in cloned embryos! 🐄🐄We started off w/ simple question: how does the somatic epigenome reprogram to prepare for the onset of transcription (EGA)? https://t.co/cNk6FNvvkp

[Kevin Tu @thekevintu]

(1/5) Our paper on pooled genetic screening of TERT-mutated #glioblastoma is out in @NaturePortfolio @oncogenejournal! We analyzed data from 500 #clinical and ~1300 #preclinical samples. Graphical abstract in the thread!
https://t.co/eu29dGV3TY

[Junzo Chino @radoncology]

ROI 5k duke crew! #astro2023

[Pete Hendrickson @pghendrickson]

Most importantly, we learned that CDS (unlike Ewing sarcoma) can probably be modeled in mice, however, innovative approaches to prevent spontaneous recombination will be required. Stay tuned!

[Pete Hendrickson @pghendrickson]

CIC-DUX4 fusion-gene driven sarcoma (CDS) is a devastating cancer that primarily affects kids and young adults. Because of its rarity, primary tissues are scarce and clinical trials are not feasible. Can we use mice instead? A thread…

[bioRxiv Cancer Bio @biorxiv_cancer]

Expression of the CIC-DUX4 fusion oncoprotein mimics human CIC-rearranged sarcoma in genetically engineered mouse models https://t.co/sw3DMtpPeb #biorxiv_cancer

[Pete Hendrickson @pghendrickson]

So what did we learn? Well, for starters, CIC-DUX4 is a very potent oncogene which seems to behave as a neomorphic transcriptional activator in line with prior findings.

[Albert Koong, MD PhD @ACKoongMDPhD]

Physician-scientists are a dying breed going from 4.7% in '80s to ~1.5% today. Multiple factors contribute including flat/declining #NIH funding. Translational research is critical for advancing clinical care.
https://t.co/bV3fxxDWPM

[Edward Grow, PhD @ControllingLMNT]

In SLC for Brad Cairns’ 25th lab anniversary. Was truly a humbling experience to be a part of great science with great scientists. We’ve spanned the gamut from biochemistry of yeast chromatin remodelers, zebrafish epigenome reprogramming, ZGA, and germline stem cells.

[Pete Hendrickson @pghendrickson]

Thanks @HenningWillers for an energizing finish to a great night @DukeRadOnc research retreat

[Pete Hendrickson @pghendrickson]

@UHN @pmcancercentre @DKirschMDPhD @DukeRadOnc @PMResearch_UHN @RadMedPM Congrats @DKirschMDPhD! No one more right for or deserving of this great opportunity.

[Pete Hendrickson @pghendrickson]

@DukeRadOnc @theNCI @chadtough Congrats Zach!

[Pete Hendrickson @pghendrickson]

@bvbal79 @DukeRadOnc @ASTRO_org @DKirschMDPhD We’ll explore the role of certain epigenetic inhibitors as radiosensitizing agents in CIC-DUX4 driven as well other soft tissue sarcomas

[Pete Hendrickson @pghendrickson]

So humbled and honored to receive this award. Thank you @ASTRO_org for recognizing our work and supporting my physician-scientist aspirations

[Duke Radiation Oncology @DukeRadOnc]

Pete Hendrickson, MD, PhD, has been selected to receive the 2022 @ASTRO_org Residents/Fellows in #RadOnc Seed Grant for his project "Ewing-like Sarcoma: Targeting the CIC-DUX4 oncogene through epigenetic regulators." @pghendrickson is mentored by @DKirschMDPhD – congrats to both!